{"id":"W4387809597","doi":"10.1016/j.annonc.2023.10.052","title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre","funders":"Daiichi Sankyo Company; MSD Italia; Eli Lilly Japan; Sanofi Genzyme; Chugai Pharmaceutical; Ipsen; AstraZeneca Pharma Poland; Eli Lilly and Company; Ono Pharmaceutical; Otsuka Pharmaceutical; Seagen; Lunit; BeiGene; Mirati Therapeutics; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; AstraZeneca España; Helsinn; Daiichi Sankyo Europe; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Spectrum Pharmaceuticals; Medtronic Japan; Amgen; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Placebo; Lung cancer; Interim; Interim analysis; Randomization; Stage (stratigraphy); Internal medicine; Pembrolizumab; Perioperative; Oncology; Tolerability; Cancer; Clinical trial; Surgery; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001355839,0.0006397478,0.001075761,0.0001881968,0.0002791627,0.001074021,0.0005680443,0.0005986035,0.001414664],"category_scores_gemma":[0.001313801,0.0004201789,0.00184117,0.0003147553,0.0003155939,0.0008516241,0.0005286822,0.001836414,0.0003236493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005420346,"about_ca_system_score_gemma":0.0005535993,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001277975,"about_ca_topic_score_gemma":0.003038442,"domain_scores_codex":[0.9994105,0.0002353681,0.00004260293,0.0001076643,0.00006193726,0.0001418786],"domain_scores_gemma":[0.9994517,0.0001179123,0.0001548508,0.00006431894,0.00004002222,0.0001711979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.307454,0.002111674,0.5964676,0.0009576629,0.01389487,0.0004486092,0.0002377543,0.001036145,0.01080764,0.0005427204,0.00331271,0.06272862],"study_design_scores_gemma":[0.01594475,0.02615592,0.9359672,0.0001931776,0.01251254,0.0004209035,0.0002694982,0.001268238,0.001436808,0.0003863,0.005374178,0.00007057016],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946433,0.003739578,0.00009050724,0.0001706893,0.00009424765,0.00003149413,0.000320403,0.000005170069,0.0009044392],"genre_scores_gemma":[0.9975036,0.000856905,0.00008202492,0.0001650003,0.00009837004,0.0000376608,0.0006149418,0.000004266997,0.0006373543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001414664,"threshold_uncertainty_score":0.007170439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09338101173832299,"score_gpt":0.4130056153629367,"score_spread":0.3196246036246138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}